Lates News
Novo Nordisk rose 1.25% in early trading on Tuesday. The company has filed a lawsuit to stop Hims & Hers Health from selling their composite semaglutide product, which they claim is unsafe and infringes on patents. After FDA warnings about enforcement actions against GLP-1 composite drugs, Hims removed their $49 pills from sale.
Latest

